{
  "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
  "docSlug": "a4fc5169399f8913c54f14d18031629c",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 64,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a table to contrast treatment efficacy and patient growth across disease stages.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/21",
  "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
  "deckJsonHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917.json",
  "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.8,
        "x": 0.1,
        "y": 0.67
      },
      "kind": "chart",
      "text": "Representative patient number growth",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5552976f-0eb0-40b0-bbb6-a979fcb9ddfa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.89
      },
      "kind": "paragraph",
      "text": "Recent studies of anti-BCMA BsAbs, ... demonstrate that patients may experience disease progression after treatment, leaving them with few other treatment options.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d964be8-e826-4015-876f-8911f1128d96",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: https://doi.org/10.1038/s41591-023-02528-9 Nature Medicine, Lancet Oncol. 2020 October ; 21(10): 1317-1330. doi:10.1016/S1470-2045(20)30452-6, ; Teclistamab in Relapsed or Refractory Multiple Myeloma New England Journal of Medicine Aug 11 2022. Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Cohen et al 2023 https://doi.org/10.1182/blood.2022015526",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48944ad9-b540-4004-92ae-b1d007df9ad5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.8,
        "x": 0.1,
        "y": 0.195
      },
      "kind": "table",
      "text": "Newly diagnosed, Standard-of-care refractory, BCMA-exposed, Representative Treatment, Results",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3caeaf35-4d6c-4a2b-bbde-a5d9c052afba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Only CAR-T in BCMA-exposed multiple myeloma, a rapidly growing patient segment (1/2)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca7d62db-3b74-49b4-bd42-b06020e497d2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "123ee5e1-9209-4a9a-af2e-1ed7fc4aa6d1",
      "evidence": "table/data: Newly diagnosed, Standard-of-care refractory, BCMA-exposed, Representative Treatment, Results",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "a64b0c09-966f-4a9f-bbc1-1e2eb73f142c",
      "evidence": "The slide uses a structured table to compare three distinct patient segments across treatment and outcome metrics.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 22,
      "from": 18,
      "beatId": "b9896073-6be4-4e40-b3ed-41f8f273601a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Clinical results and progress are highlighted.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}